Aristotle Atlantic Partners LLC Sells 1,284,275 Shares of Adaptive Biotechnologies Corporation $ADPT

Aristotle Atlantic Partners LLC reduced its holdings in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 41.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,842,444 shares of the company’s stock after selling 1,284,275 shares during the period. Adaptive Biotechnologies accounts for about 1.4% of Aristotle Atlantic Partners LLC’s investment portfolio, making the stock its 22nd largest holding. Aristotle Atlantic Partners LLC’s holdings in Adaptive Biotechnologies were worth $29,921,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Ameriprise Financial Inc. lifted its position in Adaptive Biotechnologies by 84.3% during the 3rd quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock valued at $89,337,000 after acquiring an additional 2,731,648 shares during the period. Price T Rowe Associates Inc. MD lifted its position in Adaptive Biotechnologies by 303.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock valued at $71,252,000 after acquiring an additional 3,299,635 shares during the period. Westfield Capital Management Co. LP purchased a new position in Adaptive Biotechnologies during the 4th quarter valued at about $65,942,000. Geode Capital Management LLC lifted its position in Adaptive Biotechnologies by 3.3% during the 4th quarter. Geode Capital Management LLC now owns 3,511,855 shares of the company’s stock valued at $57,041,000 after acquiring an additional 110,825 shares during the period. Finally, State Street Corp lifted its position in Adaptive Biotechnologies by 3.3% during the 4th quarter. State Street Corp now owns 3,181,644 shares of the company’s stock valued at $51,670,000 after acquiring an additional 102,362 shares during the period. 99.17% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on ADPT. Guggenheim reissued a “buy” rating and set a $21.00 price target on shares of Adaptive Biotechnologies in a research report on Wednesday, May 6th. TD Cowen lifted their price target on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Morgan Stanley decreased their target price on shares of Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating for the company in a report on Tuesday, May 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Monday, April 20th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $22.00 target price on shares of Adaptive Biotechnologies in a report on Wednesday. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $20.33.

Insider Activity at Adaptive Biotechnologies

In other Adaptive Biotechnologies news, CEO Chad M. Robins sold 83,332 shares of the company’s stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $14.41, for a total transaction of $1,200,814.12. Following the completion of the sale, the chief executive officer directly owned 2,217,781 shares of the company’s stock, valued at approximately $31,958,224.21. This represents a 3.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Francis Lo sold 39,741 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $17.49, for a total transaction of $695,070.09. Following the sale, the insider directly owned 250,934 shares of the company’s stock, valued at approximately $4,388,835.66. This represents a 13.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 589,694 shares of company stock valued at $8,945,827 over the last ninety days. Company insiders own 5.70% of the company’s stock.

Key Adaptive Biotechnologies News

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Negative Sentiment: Adaptive Biotechnologies priced an upsized $300 million offering of 0% convertible senior notes due 2031, which raises fresh capital but also signals potential dilution risk and added complexity for shareholders. The company plans to use the proceeds to repay the OrbiMed Purchase Agreement, fund capped call transactions, and repurchase $25 million of stock to help offset dilution. Article Title
• Negative Sentiment: Multiple insider sales were disclosed, including Chief Scientific Officer Harlan S. Robins selling 100,000 shares and another 6,160 shares under a 10b5-1 plan. While pre-planned, the volume of insider selling may reinforce caution around the stock. Article Title
• Neutral Sentiment: BTIG Research reaffirmed its Buy rating and kept a $22 price target, suggesting analysts still see meaningful upside from current levels. Article Title
• Neutral Sentiment: The company’s recent earnings trend remains supportive, with Q1 revenue up 35.1% year over year and results beating expectations, which helps offset some of the financing-related concerns.

Adaptive Biotechnologies Stock Down 2.6%

ADPT opened at $16.78 on Thursday. The firm has a 50 day moving average price of $14.72 and a 200-day moving average price of $15.59. Adaptive Biotechnologies Corporation has a twelve month low of $9.96 and a twelve month high of $20.76. The stock has a market capitalization of $2.69 billion, a price-to-earnings ratio of -50.85 and a beta of 2.15.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.03. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The firm had revenue of $70.87 million during the quarter, compared to analysts’ expectations of $61.03 million. During the same period in the previous year, the company earned ($0.20) earnings per share. The firm’s quarterly revenue was up 35.1% on a year-over-year basis. As a group, analysts expect that Adaptive Biotechnologies Corporation will post -0.47 earnings per share for the current year.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.